Skip to content
Open access · CC-BY via OpenAlex

A Clinically Adjusted Transcriptomic Signature for Survival Stratification in High-Grade Serous Ovarian Cancer

Aicha Lakhssassi, Mohcine Bennani Mechita, Joaira Bakkach

JCO Global Oncology · 2026

Abstract

PURPOSE High-grade serous ovarian cancer (HGSOC) remains the most lethal gynecologic malignancy, and clinical outcomes vary substantially even among patients with apparently favorable surgical cytoreduction. Improved molecular risk stratification may help identify patients at higher risk despite standard clinical prognostic features. Using publicly available transcriptomic and clinical data, we developed a compact transcriptomic signature for overall survival and assessed whether it added prognostic information beyond age, stage, and residual disease. METHODS Using TCGA-OV RNA-seq and clinical data (n = 416 HGSOC), we built a parsimonious survival signature by variance filtering, univariable Cox screening, 5-fold cross-validated LASSO-Cox, and multivariable Cox pruning. Performance was assessed on a held-out 30% test partition, in multivariable Cox adjusted for age, stage, and residual disease, and within debulking strata. Robustness was tested by 100-bootstrap resampling and consensus across Random Forest, Gradient Boosting, and L1-logistic regression. Differential expression in two additional HGSOC cohorts (n = 165 tumors) supported biological interpretation. RESULTS A nine-gene signature emerged: PRSS16, CTXN2, FCRLA (protective); PI3, LILRA2, LCN6, RNF103-CHMP3, KLK3, MTRNR2L8 (adverse). Held-out test: HR 2.15 (95% CI 1.35–3.43, p = 1.2×10 -3 ); 5-year time-dependent AUC 0.69. In multivariable Cox (n = 363), the signature was independently associated with survival (HR 1.76 per SD, P < 1×10 -10 ) and improved discrimination from C-index 0.62 to 0.69 (likelihood-ratio χ 2 = 69.6). Prognostic value was retained within R0 (no macroscopic residual) patients (HR 1.57, P = 3×10 -3 ; median survival 7.7 vs 3.8 years). Four genes (PRSS16, LILRA2, LCN6, PI3) ranked in the top 15 of all four orthogonal methods. CONCLUSION This exploratory nine-gene transcriptomic signature, derived from publicly available HGSOC transcriptomic and clinical data, stratifies overall survival and adds prognostic information beyond stage and surgical debulking. Its retained value among optimally debulked patients addresses a clinically important setting where additional risk stratification is needed. The signature reflects established TLS–mesenchymal tumor biology and nominates relatively understudied components, including CTXN2, RNF103-CHMP3, and MTRNR2L8, for orthogonal validation. External survival validation is required before clinical translation.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1200/go-26-10000
Canonical
link ↗
Fetched
2026-11-16 MST

Cite this

APA
Lakhssassi, A., Mechita, M.B., &amp; Bakkach, J. (2026). A Clinically Adjusted Transcriptomic Signature for Survival Stratification in High-Grade Serous Ovarian Cancer. <em>JCO Global Oncology</em>. https://doi.org/10.1200/go-26-10000
Vancouver
Lakhssassi A, Mechita MB, Bakkach J. A Clinically Adjusted Transcriptomic Signature for Survival Stratification in High-Grade Serous Ovarian Cancer. JCO Global Oncology. 2026. doi:10.1200/go-26-10000.
BibTeX
@article{aicha2026AClini, title = {A Clinically Adjusted Transcriptomic Signature for Survival Stratification in High-Grade Serous Ovarian Cancer}, author = {Aicha Lakhssassi and Mohcine Bennani Mechita and Joaira Bakkach}, journal = {JCO Global Oncology}, year = {2026}, doi = {10.1200/go-26-10000}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings